Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 1.3% - Time to Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s share price rose 1.3% during mid-day trading on Friday . The company traded as high as $5.84 and last traded at $5.82. Approximately 4,265,840 shares changed hands during mid-day trading, a decline of 65% from the average daily volume of 12,186,429 shares. The stock had previously closed at $5.75.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on RXRX shares. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Morgan Stanley decreased their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. KeyCorp cut their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, Leerink Partners dropped their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $8.20.

Recursion Pharmaceuticals Stock Down 2.1 %

The company has a market capitalization of $2.30 billion, a price-to-earnings ratio of -3.74 and a beta of 1.00. The firm's 50 day moving average price is $6.11 and its two-hundred day moving average price is $6.78. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The business had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals's quarterly revenue was down 57.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.42) EPS. Sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp boosted its holdings in shares of Recursion Pharmaceuticals by 1.5% during the 1st quarter. Bank of New York Mellon Corp now owns 863,224 shares of the company's stock worth $4,566,000 after buying an additional 12,588 shares during the period. D.A. Davidson & CO. grew its holdings in Recursion Pharmaceuticals by 571.7% in the 1st quarter. D.A. Davidson & CO. now owns 107,432 shares of the company's stock valued at $568,000 after buying an additional 91,438 shares in the last quarter. Kinnevik AB publ increased its position in Recursion Pharmaceuticals by 12.8% during the 1st quarter. Kinnevik AB publ now owns 13,434,171 shares of the company's stock worth $71,067,000 after buying an additional 1,528,503 shares during the period. Clear Creek Financial Management LLC lifted its holdings in shares of Recursion Pharmaceuticals by 9.8% during the first quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company's stock worth $113,000 after buying an additional 1,907 shares in the last quarter. Finally, PDS Planning Inc bought a new stake in shares of Recursion Pharmaceuticals in the first quarter valued at about $69,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.